An observational study in Adverse Drug Reactions and Clinical Decision Support, sponsored by Peking University Third Hospital. Recruiting at 2 sites in China. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Peking University Third Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China — 14 open to participants now, 15 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · China.
Among the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, this one is the 7th largest by planned enrollment of the 20 observational ones that give a count, is one of 2 that started in 2026, is one of 20 observational ones, reaches primary completion later than 12 of the 14 other live ones, and was the 53rd registered.
449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.
Browse Drug-Related Side Effects and Adverse Reactions studies →14 of the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China are open now. Recruiting first, the newest first:
Hubei Cancer Hospital · Sites in China
Ages 18–75
Eli Lilly and Company · Sites in China, United States, Australia and 7 more countries
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Guangzhou FineImmune Biotechnology Co., LTD. · Sites in China
Ages 18–75
Beijing Shijitan Hospital, Capital Medical University · Sites in China
Ages 18–64
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 55 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 37 (67%) set no upper age limit and 15 (27%) stop at 75 or younger; 14 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 2 · Phase 4 3
First in 2010; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20,000 is above the median of 414 across 162 observational studies indexed under Drug-Related Side Effects and Adverse Reactions.
Median enrollment 44 across the 33 interventional studies, 6,100 across the 20 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 53 have an industry lead sponsor. The 10 most frequent:
Peking University Third Hospital is the lead sponsor of 755 studies on the registry; 276 are open to participants now.
Peking University Third Hospital has 3 studies filed under Drug-Related Side Effects and Adverse Reactions — fewer than ten, so there is no comparison to draw.
4 of the studies in Drug-Related Side Effects and Adverse Reactions with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07169851Eli Lilly and CompanyA Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | 2026-12 |
| NCT06716619Guangzhou FineImmune Biotechnology Co., LTD.A Phase I Trial of Tumor-Associated Lymph Node T-Cell Injection With Advanced Malignant Solid Tumors | 2026-12-19 |
| NCT07264985Hubei Cancer HospitalGut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib | 2027-06 |
| NCT07808866Peking University Third HospitalMulti-Agent Collaborative ADR Prediction With Human-Machine Decision Comparison | 2027-06-19 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study develops a multi-agent collaborative prediction model to forecast adverse drug reactions using real-world clinical medical records. It validates model performance via evidence-based data and compares decision outputs between the AI model and clinical physicians, aiming to improve early identification of drug adverse events. Only de-identified historical medical data will be analyzed; no new clinical interventions will be conducted, with no additional risks to participants.
This observational study first retrospectively collects desensitization cases related to adverse drug reactions to construct a predictive model, and then prospectively enrolls patients to evaluate model efficacy and conduct comparative research with expert blind assessment.
This study includes two types of research subjects:
Retrospective de-identified adverse drug reaction (ADR) medical records: A total of 253 ADR consultation cases covering anti-infectives, cardiovascular agents, anti-tumor drugs, central nervous system drugs and digestive system drugs. Each case contains complete medical history, medication records, ADR occurrence process and clinical outcome data, as well as at least one clinically confirmed definite ADR event.
Clinical evaluators: 20 licensed physicians or pharmacists holding intermediate or higher professional titles, with clinical pharmacy practice and regular participation in hospital ADR monitoring and consultation work.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This study only analyzes de-identified historical electronic medical record data to build a multi-agent AI prediction model for adverse drug reactions. No drugs, medical devices, or clinical treatment interventions will be applied to any human subjects.
Coverage rate of known ADRs
Time frame: Up to 8 weeks
Objective question accuracy
Time frame: Up to 24 weeks
Concordance rate of predicted unknown ADRs
Time frame: Up to 8 weeks
Expert-rated subjective answer quality
Time frame: Up to 24 weeks
Subgroup differences in ADR recognition coverage rate
Time frame: Up to 24 weeks
Inter-rater consistency
Time frame: Up to 24 weeks
Subgroup differences in answer quality score
Time frame: Up to 24 weeks
Rater acceptance scale score
Time frame: Up to 24 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 65 non-industry observational studies under Drug-Related Side Effects and Adverse Reactions, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 24. This study's planned 12 months is below that.
Counting every sponsor, half of 69 studies reached it within 45 months; a quarter within 24 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Drug-Related Side Effects and Adverse Reactions →
Peking University Third Hospital →